[{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Compound Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Cholinesterase; Histone deacetylase 1; (S)-2-haloacid dehalogenase; 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supplement Formulators, Inc. \/ Compound Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Compound Solutions"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Arthritis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Cholinesterase; Histone deacetylase 1; (S)-2-haloacid dehalogenase; 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Arthritis Foundation","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Arthritis Foundation"},{"orgOrder":0,"company":"ClostraBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Histone deacetylase 1 (HDAC1)","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ClostraBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ClostraBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ClostraBio \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Fatty Acids

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Supplement Formulators, Inc.

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Supplement Formulators, Inc.

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 17, 2024

                          Lead Product(s) : Sodium Butyrate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Compound Solutions

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthritis, Rheumatoid.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 08, 2023

                          Lead Product(s) : Sodium Butyrate

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Arthritis Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : An oral, targeted metabolite delivery platform enables butyrate to achieve its maximum therapeutic potential with an initial focus on helping patients who struggle with gastrointestinal issues like mild to moderate ulcerative colitis and food allergies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 24, 2023

                          Lead Product(s) : Sodium Butyrate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank